Why Pfizer's Post-COVID Future Looks Brighter Than Ever
It's been a rough few years to be a (NYSE: PFE) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine, Comirnaty, racked up $36.8 billion in sales.
In the first half of 2025, Comirnaty sales came in at just $945 million. Sales of Paxlovid, an antiviral treatment for COVID-19, fell 60% year over year to $918 million. Despite sinking demand for Comirnaty and Paxlovid, Pfizer's post-COVID future looks bright.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Stock
€22.93
-0.280%
With 14 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 27 € there is a slightly positive potential of 17.75% for Pfizer Inc. compared to the current price of 22.93 €.
